Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1840448 | 0.91 | PTGDR2 (0.38) | BTKPTGDR2LNPEP | |
| SCHEMBL1763781 | 0.81 | SLC9A1 (0.45) | GPR119 | |
| SCHEMBL31701876 | 0.79 | PDK4 (0.49) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL1764228 | 0.78 | PDK4 (0.52) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL1763861 | 0.74 | PDK4 (0.50) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL1763951 | 0.74 | SLC9A1 (0.43) | GPR119 | |
| SCHEMBL1764048 | 0.74 | GPR119 (0.46) | NAMPTGPR119 | |
| SCHEMBL21245850 | 0.73 | PDK4 (0.53) | PDK4HTR6GRM5GRM1BTK | |
| SCHEMBL3326223 | 0.73 | PDK4 (0.65) | PDK4HTR6GRM5GRM1NAMPT | |
| SCHEMBL17222863 | 0.72 | GRM1 (0.54) | PDK4HTR6GRM5GRM1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | PDK4 717/4885HTR6 1324/4885GRM5 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.